Brought to you by 
Merck and Tesaro enter niraparib/Keytruda trial collaboration; later add use of Myriad's companion test
14 Oct 2021
Executive Summary
Merck & Co. Inc. and Tesaro Inc. will evaluate the combination of Merck's anti-PD-1 antibody Keytruda (pembrolizumab) with Tesaro's PARP-1/PARP-2 inhibitor niraparib to treat breast and ovarian cancers.
Deal Industry
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Trial Collaborations
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck and Tesaro enter niraparib/Keytruda trial collaboration; later add use of Myriad's companion test
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice